In this work, we have designed cyclic peptides (cIBL, cIBR, cIBC, CH4 and CH7) derived from the parent IB peptide (ICAM-1 1-21 ) that are inhibitors of ICAM-1/LFA-1-mediated T-cell adhesion to Caco-2 cell monolayers. Cyclic peptide cIBR has the best activity of any of the peptides evaluated. The active ICAM-1 peptides have a common Pro-Arg-Gly sequence that may be important for binding to LFA-1.
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The process of T-cell migration from the blood stream to tissues involves the interaction between lymphocyte associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1). 2 T-cell adhesion to vascular endothelial cells is mediated by the activated form of the LFA-1 integrin receptor. The activated form of LFA-1 can be induced in vivo by inflammatory cytokines and in vitro by anti CD-2 antibody or phorbol esters. 3, 4 This facilitates T-cell extravasation through vascular cell junctions into tissues containing the site of the autoimmune reaction and inflammation. Many therapies are currently being developed to treat the progression of autoimmune disease by modulating the interaction of LFA-1/ICAM-1. For example, anti-ICAM-1 and anti-CD11a monoclonal antibodies (mAb) have been shown to inhibit T-cell adhesion mediated by LFA-1 and have been developed for the treatment of rheumatoid arthritis, insulin-dependent diabetes, and psoriasis. 5, 6 Also, small organic molecules such as lovastatin, 7 p-arylthiocinnamides, and hydantoin derivatives (i.e., BRIT-377) 8, 9 have been shown to inhibit ICAM-1/LFA-1 interactions by binding to the I-domain of LFA-1.
In this work, we designed cyclic peptides that are derived from the parent linear peptide IB (ICAM-1 1-21 ) ( Table 1 ). The sequence of the linear IB peptide was derived from ICAM-1, residues 1-21 of the Domain 1 (D1) N-terminus.
The ability of peptides to inhibit ICAM-1/LFA-1 interaction was evaluated using a heterotypic cell adhesion assay between a human leukemia T-cell line (Molt-3) and Caco-2 epithelial cell monolayers, which are a model for the intestinal mucosa. 10, 11 This experimental model of T-cell adhesion to intestinal mucosa is relevant to autoimmune diseases such as Crohn's disease and ulcerative colitis. It is apparent that cIBR is the strongest inhibitor of T-cell adhesion at all concentrations ( Figure  1 ). At 500 µM cIBC is the second-most active peptide, followed by the cIBL and IB peptides, which are nearly equivalent. This result is consistent with previous findings in which the affinity of the cyclic peptides to the isolated LFA-1 receptor was also in the following order: cIBR>cIBC>cIBL. 13 These results suggest that, for cIBR and cIBC, the conformational restriction induced by cyclization may contribute to their binding affinity to LFA-1 and ability to inhibit T-cell adhesion. Both cIBR and cIBC peptides contain β-turn-like structures around this PRG sequence as determined by NMR. 14, 15 This sequence is representative of the β-hairpin turn that connects the A' and B β-strands in the D1 domain of ICAM-1. 16 The negative control, VYPNGA, demonstrated no concentrationdependent activity. The positive control RGD tripeptide demonstrated a concentration- 3 dependent ability to inhibit T-cell adhesion, presumably by inhibiting other integrins. The cIBR peptide was a distinctly better inhibitor of T-cell adhesion than was the RGD control, suggesting that the ICAM-1/LFA-1 interaction is essential for the adhesion process. This indicates that LFA-1-mediated adhesion is the preferred mechanism utilized by T-cells to adhere to epithelial cells.
The binding sites of cyclic peptides cIBL, cIBC, and cIBR were previously mapped to the Idomain of LFA-1 and at a region partially overlapping with the binding site of anti-CD11a mAb R3.1 binding site. 13 To demonstrate that ligand binding to this region of the I-domain of LFA-1 inhibits T-cell adhesion to Caco-2 monolayers, the anti-LFA-1 antibody R3.1 was also used as a positive control (Figure 2 ). The R3.1 antibody inhibited the adhesion of T-cells to monolayers in a dose-dependent manner, suggesting that the ability of these peptides to inhibit T-cell adhesion was due to their binding to this region on the I-domain (Figure 2 ). To evaluate the importance of the Pro-Arg-Gly sequence and to reduce the size of the cyclic peptide, we synthesized a series of linear hexapeptides LH1−LH8, which have overlapping sequences derived from the cIBC and cIBR peptides (Table 2 ). These peptides were evaluated at 200 µM for their ability to inhibit Tcell adhesion (Table 2) . Among these linear hexapeptides, LH4 (VILPRG) and LH7 (PRGGSV) were found to be the most effective inhibitors of T-cell adhesion. Both peptides contain a Pro-Arg-Gly (PRG) sequence, also found in cyclic peptides cIBR and cIBC. These results suggest that the sequence and structure around this PRG motif are important for the activity of these peptides. The linear hexapeptide LH4 was subjected to alanine scanning to give linear hexapeptides LHA1−LHA6 (Table 2 ). Alanine substitution of Ile2, Pro4, or Gly6 residues reduced the activity of the peptide relative to LH4. This suggests that these residues play an essential role in the ability of these peptides to recognize LFA-1 and inhibit T-cell adhesion.
To evaluate the effect of the conformation of peptides on inhibition of T-cell binding to Caco-2 monolayers, cyclic hexapeptides CH4 and CH7, which were derived from the most effective linear hexapeptides LH4 and LH7, were synthesized ( Table 1 ). The formation of cyclic hexapeptides has been shown to stabilize the β-turn structure and improve chemical and enzymatic stability. Therefore, the formation of CH4 and CH7 is expected to stabilize the β-turn at their Pro-Arg-Gly sequence as in cIBC and cIBR peptides. 15, 14 Cyclic peptide CH7 has activity similar to that of the linear LH7 ( Figure  3) . However, cyclic hexapeptide CH4 demonstrated lower activity than its linear analog LH4. These results suggest that both conformational restriction and amino acid sequence influence the activity of these peptides. This difference in activity may be due to changes in the conformation of the backbone and the side chains of PRG sequence upon cyclization. In addition, cyclization may alter the ratio of cis to trans conformation at the Xaa-Pro peptide bond in CH4 and CH7, influencing their activity. This cyclic peptide CH7 may be developed as a targeted drug delivery system to LFA-1-expressing T-cells. 17 To accommodate drug conjugation, a Lys residue was incorporated by replacing Ser5 with Lys to give peptide CHK7 ( Table 1) . Compared to CH7, the CHK7 peptide demonstrated lower activity, which suggests that the Ser5 residue is important for activity ( Figure  4 ). Figure 4 also shows that cIBR has the best inhibitory activity compared to the cyclic hexapeptides (CH4, CH7 and CHK7). In the future, other residues in CH7 will be substituted with Lys to find a derivative that maintains its LFA-1-binding activity. The binding sites of the cyclic and linear peptides on the I-domain of LFA-1 were evaluated using docking experiments. 18, 19 Previously using monoclonal antibody inhibition assay, we have determined that these peptides bind to the I-domain of LFA-1.
13 Docking studies of the cyclic peptides (cIBR, cIBC, and cIBL) reveal that these cyclic peptides have overlapping binding sites on the I-domain of LFA-1. Figure 5 shows that cIBR peptide binds at the groove region of the I-domain. Both of cIBR and cIBC peptides form hydrogen bonds to several residues on the I-domain, including Ala242, Asp244, Gln266, and Glu269. On the Our results suggest that the active ICAM-1 peptides have a common PRG sequence, which may be important for binding to LFA-1. Interestingly, another β 2 integrin (α x β 2 ) was found to have a similar proline-containing recognition sequence, GPRP, which mediates rotavirus adhesion. 20 Proline is known to stabilize β-turns. Here, Pro may stabilize the conformation of the linear peptides' PRG motif, facilitating their recognition by the LFA-1 β 2 -integrin. This has been demonstrated in RGD peptides with flanking proline residues, which help to maintain a favorable peptide conformation for recognition by β 1 -and β 3 -integrins. 21 In conclusion, we have reduced a large ICAM-1 peptide (IB) to a cyclic hexapeptide (CH7) that can bind to LFA-1 and inhibit T-cell adhesion in a concentration-dependent manner. The PRG motif may be important for the activity of these peptides. The cyclic peptide CH7 will be used to design peptidomimetics that can bind to the Idomain of LFA-1. In addition, the cyclic hexapeptide CH7 will be optimized for targeting drugs to leukocytes. The studies presented here may ultimately lead to the identification of an optimal peptide for designing small peptidomimetics that retain the activity of these ICAM-1-derived peptides.
